Table 1 Baseline characteristics.

Male, n (%)

73 (68.9%)

72 (72.0%)

0.623

Age (years)

61.7 ± 15.2

63.5 ± 13.4

0.363

Body mass index (kg/m²)

23.5 ± 3.5

25.6 ± 4.1

 < 0.001

Etiology

0.843

Ischemic cardiomyopathy, n (%)

31 (29.2%)

28 (28.0%)

Non-ischemic cardiomyopathy, n (%)

75 (70.8%)

72 (72.0%)

SBP (mm Hg)

102.8 ± 12.0

118.7 ± 13.8

 < 0.001

SBP < 100 mmHg, n (%)

40 (37.7%)

6 (6.0%)

 < 0.001

Heart rate (/min)

73.0 ± 14.6

71.6 ± 12.7

0.451

NYHA classification, n (%)

0.930

II

95 (89.6%)

90 (90.0%)

III

11 (10.4%)

10 (10.0%)

Medical history, n (%)

Hypertension

55 (51.9%)

74 (74%)

0.001

Diabetes

23 (21.7%)

36 (36%)

0.022

Dyslipidemia

13 (12.3%)

19 (19.0%)

0.172

Myocardial infarction

20 (18.9%)

23 (23.0%)

0.443

Stroke

11 (10.4%)

9 (9.0%)

0.756

Atrial fibrillation

35 (33.0%)

32 (32.0%)

0.915

Chronic kidney disease

41 (38.7%)

37 (37.0%)

0.847

Laboratory parameter

Blood urea nitrogen (mg/dL)

21.8 ± 10.6

22 ± 9.8

0.910

Creatinine (mg/dL)

1.1 ± 0.4

1.1 ± 0.4

0.854

eGFR (mL/min/1.73m²)

67.2 ± 19.9

66.2 ± 19.2

0.716

Sodium (mmol/L)

140.2 ± 2.6

140.9 ± 2.7

0.101

Potassium (mmol/L)

4.6 ± 0.5

4.6 ± 0.5

0.847

Hemoglobin (g/dL)

13.4 ± 1.8

13.8 ± 2.1

0.171

NT-proBNP (pg/mL)

2750.9 ± 4453.6

2311.1 ± 3662.1

0.475

Echocardiograhic parameter

LVEF (%)

25.4 ± 6.1

27.3 ± 5.9

0.026

LVEDD (mm)

65.5 ± 9.4

64.7 ± 7.0

0.447

Pre-SV treatment therapy

Angiotensin-converting enzyme inhibitor, n (%)

11 (10.4%)

13 (13.0%)

0.558

Angiotensin II receptor blocker, n (%)

95 (89.6%)

87 (87.0%)

0.558

Beta-blocker, n (%)

96 (90.6%)

93 (93.0%)

0.526

Mineralocorticoid receptor antagonist, n (%)

85 (80.2%)

75 (75.0%)

0.371

Loop diuretics, n (%)

89 (84%)

83 (83.0%)

0.852

Ivabradine, n (%)

21 (19.8%)

12 (12.0%)

0.127

Implantable cardioverter defibrillator, n (%)

40 (37.7%)

35 (35.0%)

0.723

Cardiac resynchronization therapy, n (%)

11 (10.4%)

15 (15.0%)

0.305